Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

689 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and Safety of Mirabegron versus Placebo Add-On Therapy in Men with Overactive Bladder Symptoms Receiving Tamsulosin for Underlying Benign Prostatic Hyperplasia: A Randomized, Phase 4 Study (PLUS).
Kaplan SA, Herschorn S, McVary KT, Staskin D, Chapple C, Foley S, Cambronero Santos J, Kristy RM, Choudhury N, Hairston J, Schermer CR. Kaplan SA, et al. Among authors: foley s. J Urol. 2020 Jun;203(6):1163-1171. doi: 10.1097/JU.0000000000000738. Epub 2020 Jan 2. J Urol. 2020. PMID: 31895002 Clinical Trial.
Mirabegron Vs Placebo Add-on Therapy in Men With Overactive Bladder Symptoms Receiving Tamsulosin for Underlying Benign Prostatic Hyperplasia: A Safety Analysis From the Randomized, Phase 4 PLUS Study.
Herschorn S, McVary KT, Cambronero Santos J, Foley S, Kristy RM, Choudhury N, Hairston J, Kaplan SA. Herschorn S, et al. Among authors: foley s. Urology. 2021 Jan;147:235-242. doi: 10.1016/j.urology.2020.09.040. Epub 2020 Oct 10. Urology. 2021. PMID: 33045287 Free article. Clinical Trial.
Reply by Authors.
Kaplan SA, Herschorn S, McVary KT, Staskin D, Chapple C, Foley S, Cambronero Santos J, Kristy RM, Choudhury N, Hairston J, Schermer CR. Kaplan SA, et al. Among authors: foley s. J Urol. 2020 Jun;203(6):1171. doi: 10.1097/JU.0000000000000738.02. Epub 2020 Mar 19. J Urol. 2020. PMID: 32191170 No abstract available.
A phase II dose-ranging study of mirabegron in patients with overactive bladder.
Chapple CR, Dvorak V, Radziszewski P, Van Kerrebroeck P, Wyndaele JJ, Bosman B, Boerrigter P, Drogendijk T, Ridder A, Van Der Putten-Slob I, Yamaguchi O; Dragon Investigator Group. Chapple CR, et al. Int Urogynecol J. 2013 Sep;24(9):1447-58. doi: 10.1007/s00192-013-2042-x. Epub 2013 Mar 8. Int Urogynecol J. 2013. PMID: 23471546 Free PMC article. Clinical Trial.
689 results